LAPRAFYLLINE is a xanthine derivative with bronchodilating effect. It might exert its action by inhibiting cAMP phosphodiesterase.

LAMTIDINE is an irreversible and specific gastric histamine H2-receptor antagonist.

KETOCAINE is a local anesthetic.

Talotrexin (also known as PT-523) was developed as a nonpolyglutamatable antifolate drug for the treatment of various types of tumors. It is known that antifolates are a class of cytotoxic or antineoplastic agents, which inhibit or prevent the maturation and proliferation of malignant cells. Talotrexin was studied in clinical trials for the treatment of brain and central nervous system tumors, leukemia, lymphoma, unspecified childhood solid tumor. However, this study was withdrawn because of toxicity. In addition, was studied in phase I/II multicenter clinical trial in patients with non-small-cell Lung carcinoma, this study was also withdrawn. The withdrawal was related to incidences of dose-limiting mucositis and myelosuppression. However, on May 22, 2006, was announced that the U.S. Food and Drug Administration has granted orphan drug designation for talotrexin in patients with acute lymphoblastic leukemia (ALL).

Sotirimod is designed to treat actinic keratosis and other conditions and is a follow-up of Aldara (active substance: imiquimod). Sotirimod and imiquimod are immunomodulatory drugs that activate the body's immune system to combat skin changes such as actinic keratosis. Sotirimod is immunostimulants and Toll-like receptor 7 agonist. Sotirimod was originally developed by 3M Pharmaceuticals, then licensed to Meda in Europe for the treatment of actinic keratosis in 2007. Sotirimod had been in phase III development for the treatment of actinic keratosis. However, there is no recent development report for this study.

Butoxylate is organic compound with significant analgesic or mydriatic activity after s.c. injection in mice and rats

Tipetropium is atropine derivative. It is the adrenoceptor agonist. Tipetropium is bronchospasmolytic agent. It was used as anti-asthmatic drug.

Beloxepin (or ADL6906), a novel dual norepinephrine reuptake inhibitor and serotonin receptor antagonist, was investigated for the treatment of the pain and Major depressive disorder, but these studies were discontinued.

Colfenamate is an antypyretic and antiinflammatory compound developed by the German company Tropon, GmbH.

Coumetarol is an anticoagulant, acting as a vitamin K antagonist, developed by the Dutch pharmaceutical company N.V. Amsterdamsche Chininefabriek. Coumetarol exhibited activity in rat models of venous and arterial thrombosis, where it was administered orally in a dose of 25 mg/kg twice daily.